Download PDF
Aktuelle Rheumatologie 2015; 40(02): 139-143
DOI: 10.1055/s-0034-1395534
Übersichtsarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Die Rolle der Komorbiditäten bei Arthritis psoriatica

Comorbidities in Psoriatic Arthritis – What is Important?
K. Krüger
1   Praxiszentrum/Rheumatologie Rheumatologie München
› Author Affiliations
Further Information

Publication History

Publication Date:
12 January 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Wie bei anderen entzündlich-rheumatischen Erkrankungen spielen auch bei der Arthritis psoriatica (PsA) Komorbiditäten eine wichtige Rolle für den Outcome und die Krankheitslast der Patienten. Das Spektrum typischer Komorbiditäten zeigt Gemeinsamkeiten, aber auch Unterschiede zur rheumatoiden.Arthritis (RA): Gemeinsam ist die dominante Rolle kardiovaskulärer Komorbiditäten, die auch die Mortalität beider Erkrankungen mitbestimmen. In engem Zusammenhang damit findet sich das metabolische Syndrom bei PsA (deutlich mehr als bei RA) gehäuft. Depression und Angststörung sind bei beiden Erkrankungen häufig und werden oft vom Rheumatologen bzw. Dermatologen übersehen.

Infektionen finden sich bei PsA häufiger als in der Normalbevölkerung aber seltener als bei der RA (möglicherweise mitbegründet durch das höhere Durchschnittsalter der RA-Patienten). Unterschiedliche Daten findet man zur Assoziation mit Malignomen, es zeigt sich allenfalls eine geringe Risikoerhöhung. Dies gilt – im Unterschied zur RA – auch für die Osteoporose. Als okuläre Komorbiditäten sind vor allem die Uveitis anterior (vor allem bei HLA-B 27-positiven Patienten) und die Blepharitis von Bedeutung. Eine Verbindung zwischen PsA/Psoriasis und anderen Autoimmunerkrankungen betrifft in erster Linie die Zöliakie und die chronisch-entzündlichen Darmerkrankungen. Wie bei der RA sollte auch bei der PsA der Rheumatologe Komorbiditäten im Blick haben und danach suchen – in praktischen Alltag bestehen hier große Defizite.

Abstract

Comorbidities play an important role for outcome and burden of disease in psoriatic arthritis as well as in other inflammatory rheumatic diseases. Addressing the typical comorbidities in PsA reveals both similarities as well as differences in comparison to RA. Most importantly, a high rate of cardiovascular complications contributing to the mortality of the disease is seen. In tight connection to that, PsA is linked to metabolic syndrome and its components. Prevalence of depression and anxiety is raised in psoriasis/PsA and in RA with equal frequency and is overlooked by rheumatologists and dermatologists very often.

The risk of infectious complications is increased in PsA but in RA a higher rate is found (possibly due to the higher mean age in the RA population). According to oncological comorbidities. we found different study results with at most a small risk elevation. This applies to osteoporosis, too, in contrast to RA. Ocular complications in psoriasis/PsA include uveitis anterior (mainly associated with HLA-B27 positivity) and blepharitis. Finally psoriasis/PsA are linked to autoimmune comorbidities with coeliac disease and inflammatory bowel diease being the most important. When treating the PsA patient, the rheumatologist should keep in mind the possibility of comorbidities and moreover should actively look for them.

Schlüsselwörter

Arthritis psoriatica - Komorbiditäten - kardiovaskuläres Risiko - metabolisches Syndrom - Depression

Key words

psoriatic arthritis - comorbidities - cardiovascular risk - metabolic syndrome - depression
 

  • Literatur

  • 1 Deutsches Rheuma-Forschungszentrum Daten der Kerndokumentation 2012 Unpubliziert
    PubMed
  • 2 Ranganath VK, Maranian P, Elashoff DA et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology 2013; 52: 1809-1817
    CrossrefPubMedGoogle Scholar
  • 3 Rupp I, Boshuizen HC, Roorda LD et al. Poor and Good Health Outcomes in Rheumatoid Arthritis: The Role of Comorbidity. J Rheumatol 2006; 33: 1488-1495
    PubMedGoogle Scholar
  • 4 Salaffi F, Carotti M, Gasparini S et al. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009; 7: 25
    CrossrefPubMedGoogle Scholar
  • 5 Schmieder A, Schaarschmidt ML, Umar N et al. Comorbidities significantly impact patients’ preferences for psoriasis treatments. J Am Acad Dermatol 2012; 67: 363-372
    CrossrefPubMedGoogle Scholar
  • 6 Ahlehoff O, Gislason GH, Charlot M et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-157
    CrossrefPubMedGoogle Scholar
  • 7 Gladman DD, Ang M, Su L et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68: 1131-1135
    CrossrefPubMedGoogle Scholar
  • 8 Rose S, Dave J, Millo C et al. Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative. Arthritis Res Ther 2014; 16: R161
    CrossrefPubMedGoogle Scholar
  • 9 Jamnitski A, Symmons D, Peters MJL et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013; 72: 211-216
    CrossrefPubMedGoogle Scholar
  • 10 Nguyen T, Wu JJ. Relationship between Tumor Necrosis Factor-α Inhibitors and Cardiovascular Disease in Psoriasis: A Review. Perm J 2014; 18: 49-54
    PubMedGoogle Scholar
  • 11 Chen YJ, Chang YT, Shen JL. Association Between Systemic Antipsoriatic Drugs and Cardiovascular Risk in Patients With Psoriasis With or Without Psoriatic Arthritis. Arthritis Rheum 2012; 64: 1879-1887
    PubMedGoogle Scholar
  • 12 Gerdes S, Mrowietz U. Komorbiditäten und Psoriasis. Hautarzt 2012; 63: 202-213
    CrossrefPubMedGoogle Scholar
  • 13 Bostoen J, Van Praet L, Brochez L et al. A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. JEADV 2014; 28: 507-511
    PubMedGoogle Scholar
  • 14 Raychaudhuri SK, Chatterjee S, Nguyen C et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 2010; 8: 331-334
    CrossrefPubMedGoogle Scholar
  • 15 Labitigan M, Bahce-Altuntas A, Kremer JM et al. Higher Rates and Clustering of Abnormal Lipids, Obesity, and Diabetes in Psoriatic Arthritis Compared with Rheumatoid Arthritis. Arthritis Care Res 2014; 66: 600-607
    CrossrefPubMedGoogle Scholar
  • 16 Dubreuil M, Rho YH, Man A et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology 2014; 53: 346-352
    CrossrefPubMedGoogle Scholar
  • 17 Wolf N, Quaranta M, Prescott NJ et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 45: 114-116
    PubMedGoogle Scholar
  • 18 Kwon HH, Kwon IH, Choi JW et al. Cross-sectional study on the correlation of serum uric acid with disease severitiy in Korean patients with psoriasis. Clin Exp Dermatol 2011; 36: 473-478
    CrossrefPubMedGoogle Scholar
  • 19 Merola JF, Wu S, Han J et al. Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis 2014; online March 20, 10.1136/annrheumdis-2014-205212
    PubMedGoogle Scholar
  • 20 Kotsis K, Voulgari PV, Tsifetaki N et al. Anxiety and Depressive Symptoms and Illness Perceptions in Psoriatic Arthritis and Associations With Physical Health-Related Quality of Life. Arthritis Care Res 2012; 64: 1593-1601
    CrossrefPubMedGoogle Scholar
  • 21 Kurd SK, Troxel AB, Paul CC et al. The Risk of Depression, Anxiety, and Suicidality in Patients With Psoriasis. Arch Dermatol 2010; 146: 891-895
    CrossrefPubMedGoogle Scholar
  • 22 Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846-850
    CrossrefPubMedGoogle Scholar
  • 23 Fortune DG, Richards HL, Kirby B et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 2003; 139: 752-756
    PubMedGoogle Scholar
  • 24 Rathbun AM, Harrold LR, Reed GW. A description of patient- and rheumatologist-reported depression symptoms in an American rheumatoid arthritis registry population. Clin Exp Rheumatol 2014; 32: 523-532
    PubMedGoogle Scholar
  • 25 Grijalva CG, Chen L, Delzell E et al. Initiation of Tumor Necrosis Factor-alpha-Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases. JAMA 2011; 306: 2331-2339
    PubMedGoogle Scholar
  • 26 Burmester GR, Panaccione R, Gordon KB et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 2013; 72: 517-524
    CrossrefPubMedGoogle Scholar
  • 27 Wakkee M, de Vries E, van den Haak P et al. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: A population-based cohort. J Am Acad Dermatol 2011; 65: 1135-1144
    CrossrefPubMedGoogle Scholar
  • 28 Abuabara K, Azfar RS, Shin DB et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol 2010; 163: 586-592
    CrossrefPubMedGoogle Scholar
  • 29 Armstrong AW, Coates LC, Espinoza LR et al. Infectious, Oncologic, and Autoimmune Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting. J Rheumatol 2013; 40: 1438-1441
    CrossrefPubMedGoogle Scholar
  • 30 Gossec L, Smolen JS, Gaujoux-Viala C et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12
    CrossrefPubMedGoogle Scholar
  • 31 Gupta AK, Lynde CW, Jain HC et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: A multicentre study. Br J Dermatol 1997; 136: 786-789
    CrossrefPubMedGoogle Scholar
  • 32 Rohekar S, Tom BDM, Hassa A et al. Prevalence of Malignancy in Psoriatic Arthritis. Arthritis Rheum 2008; 58: 82-87
    CrossrefPubMedGoogle Scholar
  • 33 Pouplard C, Brenaut E, Horreau C et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. JEADV 2013; 27 (Suppl. 03) 36-46
    PubMedGoogle Scholar
  • 34 Askling J. ARTIS Study Group . Anti-TNF therapy and risk of skin cancer, data from the Swedish ARTIS registry 1998–2006 (EULAR abstract FRI0201). Ann Rheum Dis 2009; 68: 423
    PubMedGoogle Scholar
  • 35 Raaschou P, Simard JF, Holmqvist M et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 2013; 346: f1939 DOI: 10.1136/bmj.f1939. (Published 8 April 2013)
    CrossrefPubMedGoogle Scholar
  • 36 Gross RL, Schwartzman-Morris JS, Krathen M et al. A Comparison of the Malignancy Incidence Among Patients With Psoriatic Arthritis and Patients With Rheumatoid Arthritis in a Large US Cohort. Arthritis Rheum 2014; 66: 14772-14812
    PubMedGoogle Scholar
  • 37 Husted JA, Thavaneswaran A, Chandran V et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care Res 2011; 63: 1729-1735
    PubMedGoogle Scholar
  • 38 Attia EAS, Khafagy A, Abdel-Raheem S et al. Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity. Int J Dermatol 2011; 50: 30-35
    CrossrefPubMedGoogle Scholar
  • 39 Artifoni M, Rothschild PR, Brezin A et al. Ocular inflammatory diseases associated with rheumatoid arthritis. Nat Rev Rheumatol 2014; 10: 108-116
    PubMedGoogle Scholar
  • 40 Canoui-Poitrine F, Lepka FK, FarrenQ V et al. Prevalence and Factors Associated With Uveitis in Spondylarthritis Patients in France: Results From an Observational Survey. Arthritis Care Res 2012; 64: 919-924
    CrossrefPubMedGoogle Scholar
  • 41 Durrani K, Foster S. Psoriatic Uveitis: A Distinct Clinical Entity?. Am J Ophthalmol 2005; 139: 106-111
    CrossrefPubMedGoogle Scholar
  • 42 Rehal B, Modjtahedi BS, Morse LS et al. Ocular Psoriasis. J Am Acad Dermatol 2011; 65: 1202-1212
    CrossrefPubMedGoogle Scholar
  • 43 Birkenfeld S, Dreiher J, Weitzman D et al. Coeliac disease associated with psoriasis. Br J Dermatol 2009; 161: 1331-1334
    CrossrefPubMedGoogle Scholar
  • 44 Hsu LN, Armstrong AW. Psoriasis and autoimmune disorders: A review of the literature. J Am Acad Dermatol 2012; 67: 1076-1079
    CrossrefPubMedGoogle Scholar
  • 45 Augustin M, Reich K, Glaeske G et al. Comorbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151
    CrossrefPubMedGoogle Scholar